R

Ultragenyx Pharmaceutical
D

RARE

27.340
USD
0.05
(0.18%)
مغلق
حجم التداول
42,746
الربح لكل سهم
-5
العائد الربحي
-
P/E
-5
حجم السوق
2,584,779,237
أصول ذات صلة
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
N
NTLA
0.830
(6.50%)
13.595 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
V
VYGR
-0.08000
(-2.41%)
3.23500 USD
المزيد
الأخبار المقالات

العنوان: Ultragenyx Pharmaceutical

القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.